HMGB1 and fatty liver disease: Bioinformatic and biochemical findings show that ALDH2, Niemann pick C1 (NPC1), and high mobility group protein 1 (HMGB1), which are responsible for lipid degradation and lipid homeostasis, may represent new therapeutic targets of calycosin in treatments against hepatic steatosis [97].